BeiGene, Ltd. Files Amended Annual Report with SEC

Story Highlights
BeiGene, Ltd. Files Amended Annual Report with SEC

BeiGene Ltd ( (HK:6160) ) has provided an announcement.

BeiGene, Ltd. has issued an overseas regulatory announcement regarding the filing of its amended annual report, Form 10-K/A, with the U.S. Securities and Exchange Commission. This filing is significant as it reflects the company’s compliance with regulatory requirements and provides updated financial and operational information, which is crucial for stakeholders and investors to assess the company’s current market position and future prospects.

More about BeiGene Ltd

BeiGene, Ltd. is a biotechnology company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative cancer therapies. The company is listed on The Stock Exchange of Hong Kong Limited and the Nasdaq Global Select Market, with a market presence in the United States and China.

YTD Price Performance: 52.66%

Average Trading Volume: 2,473,919

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$241.4B

See more data about 6160 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App